title: Preventing oxaliplatin-induced sensory neurotoxicity: a methodology perspective.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Chan
authors.forename: Joen
authors.initials: J
authors.lastname: Chiang
authors.forename: Kaung Yuan
authors.initials: KY
authors.lastname: Lew
authors.forename: Wen Yee
authors.initials: WY
authors.lastname: Chay
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002125:Calcium Gluconate / Q000008:administration & dosage*; D002986:Clinical Trials as Topic / Q000379:methods*; D003110:Colonic Neoplasms / Q000188:drug therapy; D057239:Early Termination of Clinical Trials; D006801:Humans; D007262:Infusions, Intravenous; D008278:Magnesium Sulfate / Q000008:administration & dosage*; D020258:Neurotoxicity Syndromes / Q000517:prevention & control; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000517:prevention & control*; D012107:Research Design; D011984:Sensory Receptor Cells / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D008278:Magnesium Sulfate; D002125:Calcium Gluconate